Sangamo Therapeutics, Inc.

What they do

Sangamo is a genomic medicine company developing zinc finger epigenetic regulators and gene therapies. Its lead programs include ST-920 (isaralgagene civaparvovec) for Fabry disease, ST-503 for chronic neuropathic pain, and ST-506 for prion disease. The company also has a capsid engineering platform, including STAC-BBB, for CNS delivery. Revenue is primarily derived from collaborations and licensing agreements.

Revenue drivers

• Collaboration and license revenue — Revenue from partnerships and licensing deals with other biopharma companies; total annual revenue was $39.6 million in 2025, down from $57.8 million in 2024.
• ST-920 (isaralgagene civaparvovec) — Gene therapy for Fabry disease; in rolling BLA submission to FDA for accelerated approval; potential future commercialization revenue but not yet approved.
• Early-stage neurology pipeline (ST-503, ST-506) — Phase 1/2 trial for ST-503 in chronic neuropathic pain; preclinical ST-506 for prion disease; no revenue yet.

Recent performance

For Q1 2026, the company reported a net loss of $31.0 million, or $0.08 per share, compared to a net loss of $30.6 million, or $0.14 per share, in Q1 2025. Revenue in Q1 2026 was $1.4 million. As of March 31, 2026, the company had cash and equivalents of $27.6 million, total assets of $60.0 million, total liabilities of $78.9 million, and negative shareholder equity of $19.0 million. The company's stock was delisted from Nasdaq and now trades on the OTCQB Venture Market.

Strategy

Sangamo is prioritizing the completion of the rolling BLA submission for ST-920 and advancing its neurology pipeline. The company is seeking substantial upfront funding through a significant partnership or other transaction for its programs. Management is implementing cost reduction measures and exploring strategic alternatives, including potential bankruptcy or liquidation. They are also pursuing business development discussions for a potential Fabry commercialization agreement.

Risks

• Going concern uncertainty — Management has stated that cash may only fund operations into the third quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Delisting from Nasdaq — The company's stock was suspended from trading on Nasdaq and moved to OTCQB; appeal hearing is scheduled for June 9, 2026, but reinstatement is uncertain.
• Dependence on external funding — Without a significant partnership or financing, the company may have to scale back operations or cease operations entirely.
• Regulatory and clinical execution risk — Rolling BLA submission for ST-920 is in progress but completion is subject to securing funding; clinical and regulatory outcomes for pipeline candidates are uncertain.

Outlook

Management expects cash to fund operations only into the third quarter of 2026 unless substantial upfront funding is secured. The BLA submission for ST-920 is expected to be completed as early as summer 2026, subject to funding. The company is pursuing strategic alternatives and may seek bankruptcy protection if necessary.